secwatch.observer — SEC 8-K summary
======================================

Issuer:     CG Oncology, Inc. (CGON)
CIK:        0001991792
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001193125-24-134805
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CG Oncology reports Q1 net loss $16.9M; cash $566.5M; cretostimogene 75.2% CR rate in BCG-unresponsive NMIBC
--------------------------------------------------------------------------------

- Net loss $16.9M ($0.36/sh) in Q1 2024 vs $12.4M ($3.22/sh) Q1 2023; R&D expense $17.2M (up from $7.8M).
- Cash and securities $566.5M as of Mar 31, 2024, compared to $187.7M at Dec 31, 2023; runway sufficient through 2027.
- Cretostimogene monotherapy achieved 75.2% complete response (79/105) in BOND-003 Phase 3 trial in BCG-unresponsive HR-NMIBC.
- Completed oversubscribed $437M IPO in 2024; first Pt dosed in PIVOT-006 Phase 3; CORE-001 combo data to be presented at ASCO June 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1991792/000119312524134805/0001193125-24-134805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1991792/000119312524134805/d774503d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-134805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer